FLUOCINOLONE ACETONIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C24H30F2O6
Molecular Weight	452.4882
Optical Activity	UNSPECIFIED
Defined Stereocenters	9 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO

InChI

InChIKey=FEBLZLNTKCEFIT-VSXGLTOVSA-N

InChI=1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C24H30F2O6
Molecular Weight	452.4882
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	9 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.drugbank.ca/drugs/DB00591
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012787s071lblrev.pdf

Fluocinolone Acetonide is a corticosteroid that binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver. Fluocinolone Acetonide is used for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (Retisert). Preparations containing Fluocinolone Acetonide were first marketed under the name Synalar.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glucocorticoid receptor 173 Target ID: CHEMBL2034 Sources: http://www.drugbank.ca/drugs/DB00591	Agonist 2752		2.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Corticosteroid-responsive dermatoses 17 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012787s071lblrev.pdf	Primary		Approved 8583	SYNALAR Approved Use SYNALAR® Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteriod-responsive dermatoses. Launch Date 1963
Chronic non-infectious uveitis affecting the posterior segment of the eye 2 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021737s000_PRNTLBL.pdf	Primary		Approved 8583	Retisert Approved Use Retisert is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. Launch Date 2005

C_max

Value	Dose	Co-administered	Analyte	Population
1.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20202684/	0.5 μg 1 times / day multiple, intraocular dose: 0.5 μg route of administration: Intraocular experiment type: MULTIPLE co-administered:		FLUOCINOLONE ACETONIDE aqueous humor	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
0 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/35988360/	0.25 mL 2 times / day multiple, auricular (otic) dose: 0.25 mL route of administration: Auricular (otic) experiment type: MULTIPLE co-administered: CIPROFLOXACIN	CIPROFLOXACIN	FLUOCINOLONE ACETONIDE plasma	Homo sapiens population: UNHEALTHY age: CHILD sex: UNKNOWN food status: UNKNOWN
54 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1874579	0.8 mg single, topical dose: 0.8 mg route of administration: Topical experiment type: SINGLE co-administered:		FLUOCINOLONE ACETONIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
354.8 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1874579	0.8 mg single, topical dose: 0.8 mg route of administration: Topical experiment type: SINGLE co-administered:		FLUOCINOLONE ACETONIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
250 day EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20202684/	0.5 μg 1 times / day multiple, intraocular dose: 0.5 μg route of administration: Intraocular experiment type: MULTIPLE co-administered:		FLUOCINOLONE ACETONIDE aqueous humor	Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
14.8 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/1874579	0.8 mg single, topical dose: 0.8 mg route of administration: Topical experiment type: SINGLE co-administered:		FLUOCINOLONE ACETONIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
6 ug 1 times / day multiple, intravitreal Highest studied dose Dose: 6 ug, 1 times / day Route: intravitreal Route: multiple Dose: 6 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15767049	unhealthy, 24 –51 Health Status: unhealthy Age Group: 24 –51 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15767049	Disc. AE: Central retinal vein occlusion... AEs leading to discontinuation/dose reduction: Central retinal vein occlusion (16.7%) Sources: https://pubmed.ncbi.nlm.nih.gov/15767049
2 ug 1 times / day multiple, intravitreal Studied dose Dose: 2 ug, 1 times / day Route: intravitreal Route: multiple Dose: 2 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15921758	unhealthy, 43.2 Health Status: unhealthy Age Group: 43.2 Sources: https://pubmed.ncbi.nlm.nih.gov/15921758	Sources: https://pubmed.ncbi.nlm.nih.gov/15921758
0.6 ug 1 times / day multiple, intravitreal Recommended Dose: 0.6 ug, 1 times / day Route: intravitreal Route: multiple Dose: 0.6 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21813090	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/21813090	Disc. AE: Increased intraocular pressure... AEs leading to discontinuation/dose reduction: Increased intraocular pressure (2.4%) Sources: https://pubmed.ncbi.nlm.nih.gov/21813090
2 ug 1 times / day multiple, intravitreal Studied dose Dose: 2 ug, 1 times / day Route: intravitreal Route: multiple Dose: 2 ug, 1 times / day Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf	unhealthy Health Status: unhealthy Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf	Other AEs: Intraocular pressure abnormal... Other AEs: Intraocular pressure abnormal Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf

AEs

AE	Significance	Dose	Population
Central retinal vein occlusion	16.7% Disc. AE	6 ug 1 times / day multiple, intravitreal Highest studied dose Dose: 6 ug, 1 times / day Route: intravitreal Route: multiple Dose: 6 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15767049	unhealthy, 24 –51 Health Status: unhealthy Age Group: 24 –51 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15767049
Increased intraocular pressure	2.4% Disc. AE	0.6 ug 1 times / day multiple, intravitreal Recommended Dose: 0.6 ug, 1 times / day Route: intravitreal Route: multiple Dose: 0.6 ug, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/21813090	unhealthy Health Status: unhealthy Sources: https://pubmed.ncbi.nlm.nih.gov/21813090
Intraocular pressure abnormal		2 ug 1 times / day multiple, intravitreal Studied dose Dose: 2 ug, 1 times / day Route: intravitreal Route: multiple Dose: 2 ug, 1 times / day Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf	unhealthy Health Status: unhealthy Sources: https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-retisert_en.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 1087 substrate 1946 inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTg5In19	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDk4OSJ9fQ%3D%3D	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTg5In19	no [IC50 >10 uM]
CYP3A4 2633	inducer 1966 Sources: https://go.drugbank.com/drugs/DB00591 \| https://pubmed.ncbi.nlm.nih.gov/23143891/	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://go.drugbank.com/drugs/DB00591 \| https://pubmed.ncbi.nlm.nih.gov/23143891/ \| https://ncit-stage.nci.nih.gov/ncitbrowser/pages/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.04d&code=C29055&ns=ncit&type=relationship&key=null&b=1&n=0&vse=null	yes
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/11724763/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:31623	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31623
ChemicalBook	CB6394372	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6394372
eMolecules	36516846	https://www.emolecules.com/cgi-bin/more?vid=36516846
eMolecules	538508	https://www.emolecules.com/cgi-bin/more?vid=538508
MolPort	MolPort-002-528-328	https://www.molport.com/shop/molecule-link/MolPort-002-528-328
Selleck Chemicals	Fluocinolone-acetonide(Flucort-N)	http://www.selleckchem.com/products/Fluocinolone-acetonide(Flucort-N).html
ZINC	ZINC000003977981	http://zinc15.docking.org/substances/ZINC000003977981

PubMed

Title	Date	PubMed
Flunisolide HFA vs flunisolide CFC: pharmacokinetic comparison in healthy volunteers.	2001 Dec	11870676
Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up.	2001 Dec	11778798
Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3).	2001 Dec	11724763
Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patients.	2001 Nov	11730183
Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients.	2001 Nov	11730179
Adrenal suppression with inhaled corticosteroids.	2001 Nov	11730176
Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants.	2001 Summer	11681651
Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion.	2002	14720057
Flunisolide HFA.	2002	14720039
Nasal cellularity in 183 unselected schoolchildren aged 9 to 11 years.	2002 Dec	12456911
Single-dose study to compare the pharmacokinetics of HFA flunisolide and CFC flunisolide.	2002 Feb	11835202
Gateways to clinical trials.	2002 Jul-Aug	12224444
Gateways to clinical trials.	2002 May	12092009
Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis.	2002 Nov	12452206
Supercritical fluids crystallization of budesonide and flunisolide.	2002 Oct	12425477
Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma.	2002 Oct	12377843
Multiple-dose proportionality study of flunisolide hydrofluoroalkane.	2002 Sep-Oct	12476540
A curious keloid of the penis.	2003	14609114
Fluocinolone acetonide 0.01% in peanut oil: therapy for childhood atopic dermatitis, even in patients who are peanut sensitive.	2003 Apr	12664021
Effect of HFA-flunisolide on peripheral lung inflammation in asthma.	2003 Jul	12847480
Clinical evaluation in treatment of oral lichen planus with topical fluocinolone acetonide: a 2-year follow-up.	2003 Jul	12787037
Recurrent oral ulceration.	2003 Jun	14596261
Triple inhaled drug protocol for the treatment of acute severe asthma.	2003 Jun	12796167
Common hyperpigmentation disorders in adults: Part II. Melanoma, seborrheic keratoses, acanthosis nigricans, melasma, diabetic dermopathy, tinea versicolor, and postinflammatory hyperpigmentation.	2003 Nov 15	14655805
Effect of topical nasal corticosteroids on patients with chronic fatigue syndrome and rhinitis.	2003 Sep	14527077
Asthma steroid pharmacogenetics: a study strategy to identify replicated treatment responses.	2004	16113459
Fluocinolone acetonide topical oil for scalp psoriasis.	2004 Dec	15764047
A comparative study of punch grafting followed by topical corticosteroid versus punch grafting followed by PUVA therapy in stable vitiligo.	2004 Jan	14692927
Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period.	2004 Jun	15279731
Rationale for the use of topical corticosteroids in melasma.	2004 Mar-Apr	15098972
Flunisolide HFA for the treatment of asthma: an old friend reformulated.	2004 May	15155115
Treatment with inhaled flunisolide.	2004 May	15136418
In vitro effects of flunisolide on MMP-9, TIMP-1, fibronectin, TGF-beta1 release and apoptosis in sputum cells freshly isolated from mild to moderate asthmatics.	2004 Sep	15291899
Enhanced anti-inflammatory potency of a nitric oxide-releasing derivative of flunisolide: role of nuclear factor-kappaB.	2004 Sep	15128863
Utilizing combination therapy to optimize melasma outcomes.	2004 Sep-Oct	15552597
Hydroquinone 4%, tretinoin 0.05%, fluocinolone acetonide 0.01%: a safe and efficacious 12-month treatment for melasma.	2005 Jan	15732437
Comparison of the analysis of corticosteroids using different techniques.	2005 Jan	15700162
Effects of drug treatment on inflammation and hyperreactivity of airways and on immune variables in cats with experimentally induced asthma.	2005 Jul	16111148
Gateways to clinical trials.	2005 Jun	16082422
The safety profile of long-term, high-dose intraocular corticosteroid delivery.	2005 Mar	15767049
Photochemistry and phototoxicity of fluocinolone 16,17-acetonide.	2005 Mar-Apr	15535735
A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads.	2005 Sep-Oct	16167418
Intravitreal steroids in the management of macular oedema.	2006 Dec	17083528
Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats.	2006 Jan-Feb	16496924
Efficacy of low-release-rate fluocinolone acetonide intravitreal implants to treat experimental uveitis.	2006 Jul	16832025
Fluocinolone acetonide intravitreal sustained release device--a new addition to the armamentarium of uveitic management.	2007	17722513
Compressor/nebulizers differences in the nebulization of corticosteroids. The CODE study (Corticosteroids and Devices Efficiency).	2007 Jul-Aug	17876957
Vitreous band formation and the sustained-release, intravitreal fluocinolone (Retisert) implant.	2007 Jun	17562999
A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.	2007 Mar	17348994
Retisert: is the new advance in treatment of uveitis a good one?	2007 Mar	17341531

Patents

Sample Use Guides

In Vivo Use Guide

generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. In hairy sites, the hair should be parted to allow direct contact with the lesion.

Route of Administration: Topical

In Vitro Use Guide

Fluocinolone Acetonide (10(−6) M) inhibited the expression of inflammatory cytokines and matrix metalloproteinases in murine immortalized keratinocytes

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:48:36 GMT 2025` Edited by `admin` on `Mon Mar 31 17:48:36 GMT 2025`
Record UNII	0CD5FD6S2M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FLUOCINOLONE ACETONIDE

Official Name

English

NEO-SYNALAR COMPONENT FLUOCINOLONE ACETONIDE

Preferred Name

English

TRI-LUMA COMPONENT FLUOCINOLONE ACETONIDE

Common Name

English

ILUVIEN COMPONENT FLUOCINOLONE ACETONIDE

Brand Name

English

fluocinolone acetonide [INN]

Common Name

English

PREGNA-1,4-DIENE-3,20-DIONE, 6,9-DIFLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (6.ALPHA.,11.BETA.,16.ALPHA.)-

Common Name

English

DERMOTIC

Brand Name

English

FLUOCINOLIDE (ACETATE)

Common Name

English

OTO-SYNALAR

Brand Name

English

FLUOCINOLONE ACETONIDE [MART.]

Common Name

English

ILUVIEN

Brand Name

English

FLUOCINOLONE ACETONIDE [USAN]

Common Name

English

SYNALAR

Brand Name

English

FLUOCINOLONE ACETONIDE [USP IMPURITY]

Common Name

English

DERMA-SMOOTHE/FS

Brand Name

English

FLUOCET

Brand Name

English

FLUOCINOLONE ACETONIDE [EP MONOGRAPH]

Common Name

English

FLUOCINOLONE ACETONIDE [HSDB]

Common Name

English

6?,9-Difluoro-11?,16?,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone

Common Name

English

FLUOCINOLONE ACETONIDE [GREEN BOOK]

Common Name

English

FLUOCINOLONE ACETONIDE [MI]

Common Name

English

FLUOCINOLONE ACETONIDE [ORANGE BOOK]

Common Name

English

FLUONID

Brand Name

English

FLUOCINOLONE ACETONIDE [VANDF]

Common Name

English

FLUOCINOLONE ACETONIDE [USP-RS]

Common Name

English

FLUOCINOLONE ACETONIDE [JAN]

Common Name

English

YUTIQ

Brand Name

English

RETISERT

Brand Name

English

OTOVEL COMPONENT FLUOCINOLONE ACETONIDE

Brand Name

English

NSC-92339

Code

English

FS SHAMPOO

Brand Name

English

FLUCINOLONE ACETONIDE

Common Name

English

FLUOCINOLONE ACETONIDE [USP MONOGRAPH]

Common Name

English

CAPEX

Brand Name

English

Fluocinolone acetonide [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QS02CA05